As the first-line treatment for DME, although anti-VEGF drugs have significant effects, up to 50% of patients still have persistent or recurrent macular edema after multiple intravitreal anti-VEGF drug injections, and their visual acuity does not improve or even decreases (28). The gene discussed is VEGFA; the disease is macular retinal edema.